ABCB1: is there a role in the drug treatment of Parkinson’s disease?

Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease

(2017) Thomas Müller   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats

(2015) Ravindrababu Pingili et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease

(2013) Thomas Müller   Expert Review of Neurotherapeutics

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

(2013) Anthony HV Schapira et al.   LANCET NEUROLOGY

ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders

(2010) Fabien Dutheil et al.   Expert Opinion on Drug Metabolism & Toxicology

Occupation and Risk of Parkinsonism

(2009) Caroline M. Tanner et al.   ARCHIVES OF NEUROLOGY

ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

(2009) Sarah Vautier et al.   Expert Opinion on Drug Metabolism & Toxicology

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA

(2008) A. L. Bartels et al.   JOURNAL OF NEURAL TRANSMISSION

Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood–brain barrier in a rat brain endothelial cell model

(2008) Sarah Vautier et al.   NEUROSCIENCE LETTERS